Lista de obras -

A New Therapeutic Strategy for Recurrent Ovarian Cancer-Bevacizumab beyond Progressive Disease

artículo científico publicado en 2019

A case of fallopian tube adenofibroma: difficulties associated with differentiation from ectopic pregnancy

artículo científico publicado en 2014

A case of ovarian adenosquamous carcinoma arising from endometrioid adenocarcinoma: a case report and systematic review

artículo científico publicado en 2016

A case of primary ovarian signet-ring cell carcinoma treated with S-1/CDDP therapy

scientific article published on 21 March 2020

A phase I study of irinotecan and pegylated liposomal doxorubicin in recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study) ⬇️

artículo científico publicado en 2014

A phase II clinical trial of palonosetron for the management of delayed vomiting in gynecological cancer patients receiving paclitaxel/carboplatin therapy

artículo científico publicado en 2015

A phase II multicenter trial of concurrent chemoradiotherapy with weekly nedaplatin in advanced uterine cervical carcinoma: Tohoku Gynecologic Cancer Unit Study

artículo científico publicado en 2008

A phase II randomized controlled study of pegylated liposomal doxorubicin and carboplatin vs. gemcitabine and carboplatin for platinum-sensitive recurrent ovarian cancer (GOTIC003/intergroup study)

scientific article published on 24 May 2019

A phase II study of irinotecan and pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study).

artículo científico publicado en 2017

A pilot study of oxaliplatin with oral S-1 as second-line chemotherapy for patients with recurrent adenocarcimona of the uterine cervix

artículo científico publicado en 2013

A recurrent ovarian cancer patient with a history of nine prior chemotherapy regimens who was safely treated with weekly paclitaxel plus bevacizumab and achieved a complete response: a case report

artículo científico publicado en 2015

A retrospective study of neoadjuvant chemotherapy plus radical hysterectomy versus radical hysterectomy alone in patients with stage II cervical squamous cell carcinoma presenting as a bulky mass

artículo científico publicado en 2016

Advanced squamous cell carcinomas arising from mature cystic teratoma of the ovary: a retrospective case series at the Tohoku Gynecologic Cancer Unit

artículo científico publicado en 2016

An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with beva

artículo científico publicado en 2018

Analysis of prognostic factors for patients with bulky squamous cell carcinoma of the uterine cervix who underwent neoadjuvant chemotherapy followed by radical hysterectomy.

artículo científico publicado en 2014

Analysis of the antitumor activity of gemcitabine and carboplatin against ovarian clear-cell carcinoma using the DNA damage marker γH2AX.

artículo científico publicado en 2013

Angiomyofibroblastoma of the vulva diagnosed preoperatively: A case report

artículo científico publicado en 2017

Anti-Mϋllerian hormone and 3D-power Doppler histogram: markers of ovarian function with in vitro fertilization treatment.

artículo científico publicado en 2010

Anti-cancer immunotherapy using cancer-derived multiple epitope-peptides cocktail vaccination clinical studies in patients with refractory/persistent disease of uterine cervical cancer and ovarian cancer [phase 2]

scientific article published on 11 November 2020

Are platinum agents, paclitaxel and irinotecan effective for clear cell carcinoma of the ovary? DNA damage detected with γH2AX induced by anticancer agents ⬇️

artículo científico publicado el 12 de junio de 2012

Case of peptide-YY-producing strumal carcinoid of the ovary: a case report and review

artículo científico publicado en 2012

Chemoradiotherapy with irinotecan (CPT-11) for adenoid cystic carcinoma of Bartholin's gland: A case report and review of the literature.

artículo científico publicado en 2012

Clinical and reproductive outcomes of fertility-sparing surgery in stage I epithelial ovarian cancer

scientific article published on 22 November 2019

Clinical efficacy of nedaplatin-based concurrent chemoradiotherapy for uterine cervical cancer: a Tohoku Gynecologic Cancer Unit Study

artículo científico publicado en 2016

Clinical significance of atypical glandular cells in the Bethesda system 2001: a comparison with the histopathological diagnosis of surgically resected specimens

artículo científico publicado en 2014

Current Status of Uterine Leiomyosarcoma in the Tohoku Region: Results of the Tohoku Translational Center Development Network Survey

artículo científico publicado en 2017

Does Severe Anemia Caused by Dose-Dense Paclitaxel-Carboplatin Combination Therapy Have an Effect on the Survival of Patients With Epithelial Ovarian Cancer? Retrospective Analysis of the Japanese Gynecologic Oncology Group 3016 Trial ⬇️

artículo científico publicado el 1 de diciembre de 2011

Effective use of everolimus as salvage chemotherapy for ovarian clear cell carcinoma: a case report

artículo científico publicado en 2014

Epigenetic modification is involved in aberrant expression of class III beta-tubulin, TUBB3, in ovarian cancer cells.

artículo científico publicado en 2008

Evaluation of postoperative chemotherapy in patients with uterine carcinosarcoma: a retrospective survey of the Tohoku Gynecologic Cancer Unit

artículo científico publicado en 2014

Fibroblast growth factor receptor 2 is associated with poor overall survival in clear cell carcinoma of the ovary and may be a novel therapeutic approach

artículo científico publicado en 2015

Gemcitabine and docetaxel in a patient with primary ovarian leiomyosarcoma: a case report and review of literature

artículo científico publicado en 2017

Identifying Prognostic Factors in Japanese Women with Pseudomyxoma Peritonei: A Retrospective Clinico-Pathological Study of the Tohoku Gynecologic Cancer Unit ⬇️

artículo científico publicado el 1 de febrero de 2011

Immunotherapy for Uterine Cervical Cancer

artículo científico publicado en 2019

Immunotherapy for Uterine Cervical Cancer Using Checkpoint Inhibitors: Future Directions

scientific article published on 27 March 2020

Investigation of the clinicopathological features of squamous cell carcinoma of the vulva: a retrospective survey of the Tohoku Gynecologic Cancer Unit.

artículo científico publicado en 2015

Loss of ARID1A expression is associated with poor prognosis in patients with stage I/II clear cell carcinoma of the ovary

artículo científico publicado en 2015

Molecular Analysis of Single Tumor Glands Using the Crypt Isolation Method in Endometrial Carcinomas

artículo científico publicado en 2016

Neoadjuvant chemotherapy using platinum- and taxane-based regimens for bulky stage Ib2 to IIb non-squamous cell carcinoma of the uterine cervix

artículo científico publicado en 2012

Neoadjuvant chemotherapy with docetaxel and carboplatin followed by radical hysterectomy for stage IB2, IIA2, and IIB patients with non-squamous cell carcinoma of the uterine cervix

artículo científico publicado en 2016

Objective evaluation of the alleviating effects of Goshajinkigan on peripheral neuropathy induced by paclitaxel/carboplatin therapy: A multicenter collaborative study ⬇️

artículo científico publicado el 24 de octubre de 2011

Paclitaxel-carboplatin for advanced or recurrent carcinosarcoma of the uterus: the Japan Uterine Sarcoma Group and Tohoku Gynecologic Cancer Unit Study

artículo científico publicado en 2014

Para-aortic lymphadenectomy may improve disease-related survival in patients with multipositive pelvic lymph node stage IIIc endometrial cancer

scientific article published on 19 July 2007

Pazopanib Maintenance Therapy in East Asian Women With Advanced Epithelial Ovarian Cancer: Results From AGO-OVAR16 and an East Asian Study

artículo científico publicado en 2015

Phase 1 study of veliparib with carboplatin and weekly paclitaxel in Japanese patients with newly diagnosed ovarian cancer

artículo científico publicado en 2017

Phase II Clinical Study of the Combination Chemotherapy Regimen of Irinotecan Plus Oral Etoposide for the Treatment of Recurrent Ovarian Cancer (Tohoku Gynecologic Cancer Unit 101 Group Study) ⬇️

artículo científico publicado el 1 de enero de 2011

Phase II clinical study of neoadjuvant chemotherapy with CDDP/CPT-11 regimen in combination with radical hysterectomy for cervical cancer with a bulky mass

scientific article published on 24 June 2016

Phase II study of tri-weekly cisplatin and irinotecan as neoadjuvant chemotherapy for locally advanced cervical cancer.

artículo científico publicado en 2010

Pilot study of intraperitoneal administration of triamcinolone acetonide for cancerous ascites in patients with end-stage gynecological cancer

artículo científico publicado en 2014

Recurrent cervical cancer in a patient who was compound heterozygous for UGT1A16 and UGT1A128 presenting with serious adverse events during irinotecan hydrochloride/nedaplatin therapy

artículo científico publicado en 2013

Results of neoadjuvant chemotherapy using tri-weekly CDDP/CPT-11 for locally advanced cervical cancer

artículo científico publicado en 2010

Safe administration of bevacizumab combination chemotherapy for the patients with recurrent cervical cancer after pelvic radiotherapy: Two case reports.

artículo científico publicado en 2018

Tako-Tsubo Cardiomyopathy Caused Immediately following Cesarean Section Delivery of Triplets: A Case Report ⬇️

artículo científico publicado el 31 de mayo de 2012

Triple simultaneous primary invasive gynecological malignancies: a case report

artículo científico publicado en 2013

Usefulness of desensitization protocol for a carboplatin hypersensitivity reaction during docetaxel-carboplatin therapy for recurrent ovarian cancer: Case report

artículo científico publicado en 2010

Yolk sac tumor of the ovary: a retrospective multicenter study of 33 Japanese women by Tohoku Gynecologic Cancer Unit (TGCU).

artículo científico publicado en 2013

Lista de obras de

A New Therapeutic Strategy for Recurrent Ovarian Cancer-Bevacizumab beyond Progressive Disease

A case of fallopian tube adenofibroma: difficulties associated with differentiation from ectopic pregnancy

A case of ovarian adenosquamous carcinoma arising from endometrioid adenocarcinoma: a case report and systematic review

A case of primary ovarian signet-ring cell carcinoma treated with S-1/CDDP therapy

A phase I study of irinotecan and pegylated liposomal doxorubicin in recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study) ⬇️

A phase II clinical trial of palonosetron for the management of delayed vomiting in gynecological cancer patients receiving paclitaxel/carboplatin therapy

A phase II multicenter trial of concurrent chemoradiotherapy with weekly nedaplatin in advanced uterine cervical carcinoma: Tohoku Gynecologic Cancer Unit Study

A phase II randomized controlled study of pegylated liposomal doxorubicin and carboplatin vs. gemcitabine and carboplatin for platinum-sensitive recurrent ovarian cancer (GOTIC003/intergroup study)

A phase II study of irinotecan and pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study).

A pilot study of oxaliplatin with oral S-1 as second-line chemotherapy for patients with recurrent adenocarcimona of the uterine cervix

A recurrent ovarian cancer patient with a history of nine prior chemotherapy regimens who was safely treated with weekly paclitaxel plus bevacizumab and achieved a complete response: a case report

A retrospective study of neoadjuvant chemotherapy plus radical hysterectomy versus radical hysterectomy alone in patients with stage II cervical squamous cell carcinoma presenting as a bulky mass

Advanced squamous cell carcinomas arising from mature cystic teratoma of the ovary: a retrospective case series at the Tohoku Gynecologic Cancer Unit

An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with beva

Analysis of prognostic factors for patients with bulky squamous cell carcinoma of the uterine cervix who underwent neoadjuvant chemotherapy followed by radical hysterectomy.

Analysis of the antitumor activity of gemcitabine and carboplatin against ovarian clear-cell carcinoma using the DNA damage marker γH2AX.

Angiomyofibroblastoma of the vulva diagnosed preoperatively: A case report

Anti-Mϋllerian hormone and 3D-power Doppler histogram: markers of ovarian function with in vitro fertilization treatment.

Anti-cancer immunotherapy using cancer-derived multiple epitope-peptides cocktail vaccination clinical studies in patients with refractory/persistent disease of uterine cervical cancer and ovarian cancer [phase 2]

Are platinum agents, paclitaxel and irinotecan effective for clear cell carcinoma of the ovary? DNA damage detected with γH2AX induced by anticancer agents ⬇️

Case of peptide-YY-producing strumal carcinoid of the ovary: a case report and review

Chemoradiotherapy with irinotecan (CPT-11) for adenoid cystic carcinoma of Bartholin's gland: A case report and review of the literature.

Clinical and reproductive outcomes of fertility-sparing surgery in stage I epithelial ovarian cancer

Clinical efficacy of nedaplatin-based concurrent chemoradiotherapy for uterine cervical cancer: a Tohoku Gynecologic Cancer Unit Study

Clinical significance of atypical glandular cells in the Bethesda system 2001: a comparison with the histopathological diagnosis of surgically resected specimens

Current Status of Uterine Leiomyosarcoma in the Tohoku Region: Results of the Tohoku Translational Center Development Network Survey

Does Severe Anemia Caused by Dose-Dense Paclitaxel-Carboplatin Combination Therapy Have an Effect on the Survival of Patients With Epithelial Ovarian Cancer? Retrospective Analysis of the Japanese Gynecologic Oncology Group 3016 Trial ⬇️

Effective use of everolimus as salvage chemotherapy for ovarian clear cell carcinoma: a case report

Epigenetic modification is involved in aberrant expression of class III beta-tubulin, TUBB3, in ovarian cancer cells.

Evaluation of postoperative chemotherapy in patients with uterine carcinosarcoma: a retrospective survey of the Tohoku Gynecologic Cancer Unit

Fibroblast growth factor receptor 2 is associated with poor overall survival in clear cell carcinoma of the ovary and may be a novel therapeutic approach

Gemcitabine and docetaxel in a patient with primary ovarian leiomyosarcoma: a case report and review of literature

Identifying Prognostic Factors in Japanese Women with Pseudomyxoma Peritonei: A Retrospective Clinico-Pathological Study of the Tohoku Gynecologic Cancer Unit ⬇️

Immunotherapy for Uterine Cervical Cancer

Immunotherapy for Uterine Cervical Cancer Using Checkpoint Inhibitors: Future Directions

Investigation of the clinicopathological features of squamous cell carcinoma of the vulva: a retrospective survey of the Tohoku Gynecologic Cancer Unit.

Loss of ARID1A expression is associated with poor prognosis in patients with stage I/II clear cell carcinoma of the ovary

Molecular Analysis of Single Tumor Glands Using the Crypt Isolation Method in Endometrial Carcinomas

Neoadjuvant chemotherapy using platinum- and taxane-based regimens for bulky stage Ib2 to IIb non-squamous cell carcinoma of the uterine cervix

Neoadjuvant chemotherapy with docetaxel and carboplatin followed by radical hysterectomy for stage IB2, IIA2, and IIB patients with non-squamous cell carcinoma of the uterine cervix

Objective evaluation of the alleviating effects of Goshajinkigan on peripheral neuropathy induced by paclitaxel/carboplatin therapy: A multicenter collaborative study ⬇️

Paclitaxel-carboplatin for advanced or recurrent carcinosarcoma of the uterus: the Japan Uterine Sarcoma Group and Tohoku Gynecologic Cancer Unit Study

Para-aortic lymphadenectomy may improve disease-related survival in patients with multipositive pelvic lymph node stage IIIc endometrial cancer

Pazopanib Maintenance Therapy in East Asian Women With Advanced Epithelial Ovarian Cancer: Results From AGO-OVAR16 and an East Asian Study

Phase 1 study of veliparib with carboplatin and weekly paclitaxel in Japanese patients with newly diagnosed ovarian cancer

Phase II Clinical Study of the Combination Chemotherapy Regimen of Irinotecan Plus Oral Etoposide for the Treatment of Recurrent Ovarian Cancer (Tohoku Gynecologic Cancer Unit 101 Group Study) ⬇️

Phase II clinical study of neoadjuvant chemotherapy with CDDP/CPT-11 regimen in combination with radical hysterectomy for cervical cancer with a bulky mass

Phase II study of tri-weekly cisplatin and irinotecan as neoadjuvant chemotherapy for locally advanced cervical cancer.

Pilot study of intraperitoneal administration of triamcinolone acetonide for cancerous ascites in patients with end-stage gynecological cancer

Recurrent cervical cancer in a patient who was compound heterozygous for UGT1A1*6 and UGT1A1*28 presenting with serious adverse events during irinotecan hydrochloride/nedaplatin therapy

Results of neoadjuvant chemotherapy using tri-weekly CDDP/CPT-11 for locally advanced cervical cancer

Safe administration of bevacizumab combination chemotherapy for the patients with recurrent cervical cancer after pelvic radiotherapy: Two case reports.

Tako-Tsubo Cardiomyopathy Caused Immediately following Cesarean Section Delivery of Triplets: A Case Report ⬇️

Triple simultaneous primary invasive gynecological malignancies: a case report

Usefulness of desensitization protocol for a carboplatin hypersensitivity reaction during docetaxel-carboplatin therapy for recurrent ovarian cancer: Case report

Yolk sac tumor of the ovary: a retrospective multicenter study of 33 Japanese women by Tohoku Gynecologic Cancer Unit (TGCU).

Recurrent cervical cancer in a patient who was compound heterozygous for UGT1A16 and UGT1A128 presenting with serious adverse events during irinotecan hydrochloride/nedaplatin therapy